This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | MicrobiomeTrials
← Back to trials NCT07770698
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-12Est. Completion: 2030-04-30
Enrollment target: 30 participantsOther microbiome trials you might be interested in Malignancy, Hematologic Neoplasms, Hematologic Neoplasms, Hematopoietic Blood Cancer Hematological Neoplasms Hematopoietic Malignancies Dysmyelopoietic Syndromes Hematopoetic Myelodysplasia Myeloid Leukemia, Acute Nonlymphoblastic Leukemia, Acute Leukemia, Lymphocytic, Acute
Background:
Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…
Bethesda, United States Est. completion Apr 30, 2029
Phase 2
Recruiting
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and v…
Birmingham, United States Est. completion Dec 31, 2027